CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AEWS07B1 | COG | A COG Study for Collecting and Banking Ewing Sarcoma Specimens | Pediatric CIRB | Available to Open |
| ACNS1021 | COG | A Phase II Study of Sunitinib (NSC# 736511; IND# 74019) in Recurrent; Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients | Pediatric CIRB | Completed |
| ANBL1531 | COG | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | Pediatric CIRB | Available to Open |
| ACCL0935 | COG | Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk | Pediatric CIRB | Completed |
| AOST2032 | COG | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma | Pediatric CIRB | Available to Open |
| AALL08P1 | COG | Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study | Pediatric CIRB | Completed |
| ALTE05N1 | COG | Umbrella Long-Term Follow-Up Protocol | Pediatric CIRB | Available to Open |
| AREN0532 | COG | Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |
| ADVL1315 | COG | A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA; 123101) in Children with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed |
| ACNS0332 | COG | Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients: A Groupwide Phase III Study | Pediatric CIRB | Available to Open |